Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC DOI
Fabiana Perrone, Alessandro Leonetti, Marcello Tiseo

et al.

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(8), P. 1128 - 1132

Published: Aug. 1, 2024

Language: Английский

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer DOI Creative Commons
Mark M. Awad, Patrick M. Forde, Nicolas Girard

et al.

Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

PURPOSE Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable are limited. We report results from the exploratory concurrently and chemotherapy arms of international phase III CheckMate 816 trial. METHODS Adults stage IB-IIIA (American Joint Committee on Cancer seventh edition) NSCLC received three cycles once every 2 weeks one cycle or (on day 1 days 8 each 3-week cycle) followed by surgery. Analyses included event-free (EFS), OS, pathologic response, surgical outcomes, biomarker analyses, safety. RESULTS A total 221 patients were randomly assigned to (n = 113) 108). At a median follow-up 49.2 months, EFS was 54.8 months (95% CI, 24.4 not reached [NR]) versus 20.9 14.2 NR) (HR, 0.77 [95% 0.51 1.15]); 3-year rates 56% 44%. Higher events initially seen, later benefit favoring ipilimumab; OS 73% 61% 0.73 0.47 1.14]); complete response 20.4% 4.6%, respectively. In respective arms, 83 (74%) 82 (76%) underwent definitive Grade 3-4 treatment-related adverse occurred 14% 36% patients, CONCLUSION showed potential long-term clinical chemotherapy, despite early crossing curves preoperative lower rate high-grade toxicity.

Language: Английский

Citations

0
Comparative effectiveness of nivolumab and ipilimumab plus chemotherapy versus pembrolizumab plus chemotherapy in PD-L1 negative metastatic non-small cell lung cancer patients DOI
Marjon V. Verschueren,

Dagmar T A Hiensch,

Peter J. A. M. PLOMP

et al.

Clinical Lung Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels DOI
Aws Khalid Abushanab, Mus’ab Theeb Mustafa, Mahmoud Taysir Mousa

et al.

Expert Review of Anticancer Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Background Immune checkpoint inhibitors (ICIs) are currently the primary approach for managing NSCLC. However, numerous combination therapies under investigation. Our goal is to investigate overall efficacy and safety of ICIs taxane-based chemotherapy.

Language: Английский

Citations

0
Traitement standard de première ligne des carcinomes bronchiques non à petites cellules métastatiques sans addiction oncogénique DOI

Romane Gille,

M. Pérol

Bulletin du Cancer, Journal Year: 2025, Volume and Issue: 112(3), P. 3S64 - 3S74

Published: March 1, 2025

Language: Английский

Citations

0
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study DOI
Akito Miyazaki, Kei Kunimasa, Toshitaka Morishima

et al.

ESMO Real World Data and Digital Oncology, Journal Year: 2025, Volume and Issue: 8, P. 100137 - 100137

Published: April 14, 2025

Language: Английский

Citations

0
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial DOI
Matthias Gückenberger, Isabelle Opitz,

Tereza Dellaporta

et al.

Lung Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 108553 - 108553

Published: April 1, 2025

Language: Английский

Citations

0
Microbiota-centered interventions to boost immune checkpoint blockade therapies DOI
Andrew A. Almonte,

Simon Thomas,

Laurence Zitvogel

et al.

The Journal of Experimental Medicine, Journal Year: 2025, Volume and Issue: 222(7)

Published: April 22, 2025

Immune checkpoint blockade therapies have markedly advanced cancer treatment by invigorating antitumor immunity and extending patient survival. However, therapeutic resistance immune-related toxicities remain major concerns. Emerging evidence indicates that microbial dysbiosis diminishes response rates, while a diverse gut ecology key beneficial taxa correlate with improved outcomes. Therefore, there is growing understanding manipulating the microbiota could boost therapy efficacy. This review examines burgeoning methods target microbiome to optimize innovative diagnostic tools detect dysbiosis, highlights challenges be addressed in field.

Language: Английский

Citations

0
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis DOI Creative Commons
Solange Peters, Luis Paz‐Ares, Martin Reck

et al.

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 20(1), P. 94 - 108

Published: Oct. 4, 2024

Language: Английский

Citations

3
NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma DOI Creative Commons
Xin Chen,

Tao Zhang,

Yan‐qiu He

et al.

BMC Pulmonary Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: May 19, 2024

Abstract Background Neuronal guanine nucleotide exchange factor (NGEF) plays a key role in several cancers; however, its lung adenocarcinoma (LUAD) remains unclear. The aim of this study was to evaluate the efficacy NGEF as prognostic biomarker and potential therapeutic target for LUAD. Methods expression data multiple cancers LUAD were downloaded from databases. high- low-NGEF groups constructed based on median samples, then performed Kaplan–Meier survival analysis. Differentially expressed genes (DEGs) two screened applied construct protein-protein interaction network. primary pathways obtained using gene set enrichment associations between clinical characteristics, immune infiltration, checkpoint inhibitors (ICIs), sensitivity chemotherapy, tumor mutation burden (TMB) investigated R. Levels tissue validated single-cell RNA sequencing, quantitative polymerase chain reaction (qPCR), immunohistochemical staining, western blot Results mRNA upregulated cancers. protein levels higher patients with than controls, qPCR blot. High an independent associated advanced stage, large size, more lymph node metastasis, worse overall (OS). A total 182 overlapping DEGs Cancer Genome Atlas GSE31210, among which top 20 hub identified. mainly enriched apoptosis, cell cycle, DNA replication. Moreover, elevated high fraction activated memory CD4 + T cells M 0 macrophages; ICIs: programmed death 1 ligand expression; TMB; better bortezomib, docetaxel, paclitaxel, parthenolide, but less axitinib metformin. Conclusion is significantly stages, OS probability, immunotherapy response, chemotherapy response. may be diagnostic

Language: Английский

Citations

2
Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1 DOI Creative Commons
Alessandro Morabito

Drugs in Context, Journal Year: 2024, Volume and Issue: 13, P. 1 - 8

Published: July 18, 2024

The advent of immunotherapy, and in particular the use immune-checkpoint inhibitors, has profoundly revolutionized treatment different cancers, including lung cancer. inhibitors prolonged survival cancer with a strong benefit significant percentage patients non-small-cell Here, clinical case patient who, despite testing negative for PD-L1, displayed sustained complete response to immunotherapy advanced metastatic is presented. Additionally, recent findings concerning application this context are reviewed.

Language: Английский

Citations

1